Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.

Biotechnology

Guardant Health

Co-CEOs

As Chief Medical Officer, Dr. Eagle plays a vital role in furthering [Guardant Health](/org/guardant-health)’s mission of transforming cancer care by unlocking data that will accelerate precision oncology for patients at all stages of the disease.

Prior to joining [Guardant Health](/org/guardant-health), Dr. Eagle has most recently served as Vice President of Medical Affairs Oncology for [Genentech](/org/genentech) where he oversaw the medical programs across the oncology portfolio, and developed innovative cancer trials and strategies in personalized health care. Prior to [Genentech](/org/genentech), Dr. Eagle has held several positions in the U.S. and internationally over his 19-year career at [Pfizer](/org/pfizer) including global head of the Oncology Medical and Outcomes Group. In this role, he oversaw the worldwide medical programs and development of numerous commercially successful drugs. Dr. Eagle currently serves on the Board of Directors for [Generex Biotechnology](/org/generex-biotechnology) and NuGenerex Immuno-Oncology.

Dr. Eagle attended medical school at the University of New South Wales in Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney. Dr. Eagle completed his specialist training in hemato-oncology and laboratory hematology at Royal Prince Alfred Hospital in Sydney and was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA).

Craig Eagle

Steven Collora is the Vice President of Sales at [Guardant Health](/org/guardant-health). Prior to their current role, Steven served as the Director of Corporate Development at Precision Therapeutics, where they were the strategic lead of senior management and had project and team responsibility focusing on six key functions, including product marketing, GPO & IDN contract negotiations, national account and KOL development and management, national speaker training and medical ad-board oversight, commercialization strategy for new product launches, and national sales training.

Steven began their career in the pharmaceutical industry at Pfizer, Inc. where they completed their Leadership Development Program and served as a Professional Healthcare Representative. Steven then went on to work as an Account Executive at Levenson & Brinker Public Relations before taking on the role of Director of Public Relations at OFB, Inc.

Under Steven’s leadership, [Guardant Health](/org/guardant-health) has seen significant growth and success. Steven has been instrumental in developing and executing Guardant’s sales strategy, which has resulted in increased market share and revenue. In addition, Steven has built and managed a strong sales team that is focused on meeting and exceeding customer expectations.

Steven Collora has a Bachelor of Arts in Communications & Pre-Med from The University of Texas at Arlington and a Master of Arts in Communication from [Lamar University](/org/lamar-university). Steven is currently a PhD candidate in Communications at the [University of Utah](/org/university-of-utah).

Some of their coworkers include Bill Getty - SVP, Commercial Screening. Steven Collora reports to Chris Freeman, Chief Commercial Officer.

Steven Collora

Kumud Kalia is the current CIO at [Guardant Health](/org/guardant-health). Prior to this, they served as the Chief Information & Technology Officer at Cylance Inc. from March 2018 to June 2019. Kumud has also served as the Chief Information Officer at [Akamai Technologies](/org/akamai-technologies) from October 2011 to February 2018, and as CIO & EVP Customer Operations at [Direct Energy](/org/direct-energy) from March 2005 to January 2011. In addition, Kumud served as VP at Qwest Communications from June 2002 to July 2004, where they were responsible for the CIO function for the Business Markets Group, e-Business, Finance, Marketing, HR, Legal, and Risk Management lines of business or functions. Prior to that, Kumud was the CIO at Dresdner Kleinwort Wasserstein from April 1998 to June 2002, where they provided consulting services and led client engagements in telecom, software, and e-commerce. Kumud also served as President at Lone Tree Executive Solutions from July 2004 to March 2005 and as a Consultant at their own firm from October 1996 to April 1998. Kumud began their career in 1990 as a Technology Manager at [Morgan Stanley](/org/morgan-stanley) and later served as Technology and Operations Manager at UBS Investment Bank from October 1993 to October 1996.

Kumud Kalia has a Master's degree in Information and Cyber Security from the University of California, Berkeley. They also have a BSc in Electronic Engineering from [Bangor University](/org/bangor-university). In addition, they are certified by the BCS, The Chartered Institute for IT as a Chartered IT Professional (CITP), and by the Engineering Council as a Chartered Engineer (CEng).

Kumud Kalia works with Craig Eagle - Chief Medical Officer, Chris Freeman - Chief Commercial Officer, and Doug Dolginow - VP, Product Management. Kumud Kalia reports to Helmy Eltoukhy, Co-CEO.

Kumud Kalia

Helmy Eltoukhy is the Co-CEO of [Guardant Health](/org/guardant-health). Helmy has a long history of working in the field of sequencing and related technologies. Helmy started their career at Aurum Capital Management as an Analyst/Programmer. Helmy then moved to Stanford Genome Technology Center as a Postdoctoral Fellow, researching novel assays and detection modalities for nucleic acid analysis. In 2006, they became the President & CEO of Avantome, where they were responsible for Financing, Corporate Development, Business Development, Operations, Research, Technology Development, Commercial Operations, and Branding. In 2007, they joined [Illumina](/org/illumina) as Sr. Director, [Advanced Technology Group](/org/advanced-technology-group). Helmy worked on Novel Sequencing Biochemistry R&D, Novel Sensor/Detection for Sequencing R&D, Long read sequencing R&D, and Novel Sequencing Instrument Architecture R&D. Helmy also worked on Large Scale Integration for Genetic Analysis and Semiconductor-based Genetic Analysis Systems. In 2012, they left [Illumina](/org/illumina) to co-found [Guardant Health](/org/guardant-health), where they are currently Co-CEO.

Helmy Eltoukhy has a PhD in Electrical Engineering from [Stanford University](/org/stanford). Helmy also has an MS in Electrical Engineering from [Stanford University](/org/stanford), and a BS in Electrical Engineering from [Stanford University](/org/stanford).

Andy Ament - SVP, Operations, Kumud Kalia - CIO, and Darl Moreland - SVP, Regulatory & Quality report to Helmy Eltoukhy.

Helmy Eltoukhy

Bill Getty is the Senior Vice President of Commercial Screening at [Guardant Health](/org/guardant-health). Prior to their current role, Bill served as the Vice President of Oncology Marketing at [Guardant Health](/org/guardant-health) from April 2017 to January 2021. Previously, they were the Executive Director of Oncology Marketing at [Exelixis](/org/exelixis) from November 2016 to April 2017 and the XTANDI Marketing Director at Medivation from November 2015 to November 2016. Before their time at Medivation, Bill served as the Director/Team Leader of Xtandi Portfolio Planning from September 2013 to November 2015. Bill began their career at [Pfizer](/org/pfizer) in January 2012 as the Director of Strategy/Commercial Solutions for the Emerging Markets & Established Products Business Unit and held this role until September 2013. In January 2010, they were promoted to Senior Finance Manager of the Emerging Markets Business Unit and held this role until January 2012. From April 2007 to January 2010, Bill served as the Finance Manager for the Worldwide Biopharma Business. Bill began their career at [Pfizer](/org/pfizer) as a Therapeutic Specialty Representative in the Powers Division from September 2006 to January 2007 before being promoted to Professional Healthcare Representative in the Steere Division from May 2003 to September 2006.

Bill Getty's educational career includes a Bachelor of Science in Biology from the University of Massachusetts, Amherst and a Masters in Business Administration with a focus in Finance from [Fairleigh Dickinson University](/org/fairleigh-dickinson-university).

Their manager is Chris Freeman, Chief Commercial Officer. They are on a team with and Steven Collora - VP, Sales.

Bill Getty

John Saia is the SVP, General Counsel & Corporate Secretary at [Guardant Health](/org/guardant-health). Prior to [Guardant Health](/org/guardant-health), John was the SVP, General Counsel and Corporate Secretary at [WageWorks](/org/wageworks) from January 2019 to December 2019. At [WageWorks](/org/wageworks), John was responsible for leading the fintech SaaS provider of consumer-directed benefits with more than 75,000 customers, including most of the Fortune 100, generating annual revenue of nearly $500 million supported by over 2,200 employees across six main office locations. John was recruited to turn around the legal and compliance functions following the announcement of a multiyear financial restatement. John reported to the CEO and redesigned the legal, corporate governance, intellectual property, compliance and related risk management functions by clarifying roles and responsibilities for each of the 20 professionals spread across four office locations. John was able to reduce outside counsel expense by more than 50% by both consolidating vendors down to five from more than a dozen, and by bringing routine legal and compliance support in-house. John resolved the multi-year financial restatement by filing of more than a dozen reports with the [Securities and Exchange Commission](/org/sec) in a period of four months, which once completed, more than doubled the company’s market capitalization. John successfully negotiated a sale of the company to HealthEquity, Inc. (NASDAQ: HQY) for approximately $2.2 billion, which included an accelerated market check with more than a dozen potential private and public company partners. Lastly, John led the litigation defense strategy for the dozens of derivative, class action and government investigations that stemmed from the financial restatement commenced in 2018.

John Saia earned their JD from The George Washington University Law School and their BS & BA in Political Science & Economics from [Santa Clara University](/org/santa-clara-university). John also completed an Executive Education Leadership Program at The Wharton School and a Leadership Graduate Program at the Global Institute for Leadership Development (GILD).

John Saia reports to Helmy Eltoukhy, Co-CEO. They work with Craig Eagle - Chief Medical Officer, Chris Freeman - Chief Commercial Officer, and Jennifer Higgins - VP, Public Affairs.

John Saia

Michael Bell is the current Chief Financial Officer at [Guardant Health](/org/guardant-health). Prior to this, they held the same position at CareDx, Inc. from April 2017 to December 2020. Before that, they were the Chief Financial Officer & SVP at [Singulex](/org/singulex) from January 2012 to December 2016. 

Bell has extensive experience in finance, having also served as the Chief Financial Officer for [Novartis](/org/novartis)' Diagnostics division from January 2006 to December 2012, as well as Director of Finance for Chiron Corporation from January 2005 to December 2006. Michael began their career in finance as an Auditor for Ernst & Young from January 1993 to December 1997, before being promoted to Senior Manager from January 2001 to December 2005.

Michael Bell completed a BSc in Mathematics & Computing at the [University of Leicester](/org/university-of-leicester). Michael then went on to achieve certification as a Fellow Chartered Accountant (FCA) from the ICAEW.

Their manager is Helmy Eltoukhy, Co-CEO. They are on a team with Daniel Simon - SVP, Biopharma Business Development, Michael Wiley - Head of Corporate Affairs, and Chris Freeman - Chief Commercial Officer.

Michael Bell

Jennifer Higgins is the Vice President of Public Affairs at [Guardant Health](/org/guardant-health). Jennifer has over six years of experience in the public affairs field, with a focus on health care, tax, and immigration. Prior to their current position, Jennifer was a Partner at Chamber Hill Strategies, where they provided strategic counsel on legislative initiatives, regulatory matters, and political positioning for a variety of clients. Jennifer has also worked as a Principal at Tauzin Consultants, LLC, where they educated and advised Members of Congress and their staff, along with key Administration officials on client issues and objectives. Jennifer is a well-respected figure in the public affairs community, and has been keynote speaker at various events. Jennifer is known for their policy memos on complex health policy issues for senior executives and their lobbyists.

Jennifer Higgins has completed a certificate in Legislative Studies from [Georgetown University](/org/georgetown-university), a Bachelor of Arts in Medical Economics and Ethics (CIS) from [Davidson College](/org/davidson-college), and a certification from Harvard Medical School in HMX Pro Genetics - Cancer Genomics and Precision Oncology. Jennifer is currently enrolled in a Coursera course in Introduction to the Biology of Cancer and has also completed a Coursera course in An Introduction to American Law.

Their manager is Helmy Eltoukhy, Co-CEO. They work with John Saia - SVP, General Counsel & Corporate Secretary, Michael Wiley - Head of Corporate Affairs, and Andy Ament - SVP, Operations.

Jennifer Higgins

Chris Freeman is the current Chief Commercial Officer at [Guardant Health](/org/guardant-health). Prior to this, Chris was the Vice President, HIV Business Unit Head at [Gilead Sciences](/org/gilead-sciences) from May 2011 to June 2021. In this role, Chris lead Gilead's $13B HIV treatment and prevention businesses and was responsible for the launch of Veklury (remdesivir) for emergency use authorization to treat COVID-19. Prior to Gilead, Chris was at Elan from October 2008 to May 2011 as the Director, Strategic Marketing & Alliance Management. In this role, Chris was the strategic marketing lead for Tysabri in Multiple Sclerosis and Crohn's Disease and the commercial lead for Alzheimer's pipeline products including ELND005 (P2) and Gamma (preIND). Chris was also responsible for ensuring the successful execution of partnered programs including the Alzheimer’s Immunotherapy Program (AIP) with Wyeth/Pfizer and J&J, Tysabri with Biogen Idec and ELND005 with Transition Therapeutics. Before Elan, Chris was at [Genentech](/org/genentech), Inc as the Group Manager, Oncology & Asthma Marketing from December 2001 to October 2008. Prior to [Genentech](/org/genentech), Chris served in the U.S. Army as a Captain in Armor from June 1996 to December 2001.

Chris Freeman has a BS in Chemistry and Life Sciences from the United States Military Academy at West Point. Chris also has an MA in Human Resources from [Central Michigan University](/org/central-michigan-university). Chris is currently a Doctoral Candidate in Marketing at Golden Gate University.

Chris Freeman reports to Helmy Eltoukhy, Co-CEO. Some individuals on their team include Bill Getty - SVP, Commercial Screening, Steven Collora - VP, Sales. Chris Freeman works with Michael Bell - CFO, Darya Chudova - SVP, Technology, and Craig Eagle - Chief Medical Officer.

Chris Freeman

AmirAli Talasaz is the Co-CEO at [Guardant Health](/org/guardant-health). Prior to this, they were Sr. Director, Scientific Research at [Illumina](/org/illumina) from March 2009 to June 2012. Before [Illumina](/org/illumina), AmirAli was Co-founder at Auriphex Biosciences from January 2008 to March 2009 and an Engineering Research Associate and Technology Lead at Stanford Genome Technology Center from January 2007 to March 2009.

AmirAli Talasaz has a Ph.D. in Electrical Engineering from [Stanford University](/org/stanford), a Master's degree in Management Science and Engineering from [Stanford University](/org/stanford), and a B.Sc. in Electrical Engineering from Sharif University of Technology.

AmirAli Talasaz

Amelia Merrill is the SVP of People at [Guardant Health](/org/guardant-health). Amelia has over 10 years of experience in talent acquisition, engagement, and HR operations. Prior to [Guardant Health](/org/guardant-health), Amelia was with RMS for 4 years where they served as the VP of Talent Acquisition, Engagement & HR Operation. Amelia has also been an Advisory Board Member for RolePoint and Advisor for Wepow and a CPOHQ Member.

Amelia Merrill graduated from California Polytechnic State University-San Luis Obispo with a degree in Agricultural Business and Management. Amelia then went on to work in the agricultural business and management field.

Amelia Merrill reports to Helmy Eltoukhy, Co-CEO. They are on a team with Michael Wiley - Head of Corporate Affairs, John Saia - SVP, General Counsel & Corporate Secretary, and Darya Chudova - SVP, Technology.

Amelia Merrill

Michael joined [Guardant Health](/org/guardant-health) in 2012 as President and became its Chief Financial Officer in 2013 and its Chief Legal Officer in 2016. Prior to joining Guardant, Michael worked as CFO at Voyage Medical, a medical device company. Before Voyage, Michael was VP of Finance at Microchip Biotechnologies, Inc., where he led the team that raised both Series A and Series B financings for the company. Earlier in his career, Michael was a corporate attorney at Venture Law Group and acted as in-house associate counsel for Novell where he focused on intellectual property and employment issues. Before receiving a JD J. Reuben Clark Law School at Brigham Young University, Michael worked for [KPMG](/org/kpmg) as a tax accountant.

Michael Wiley

Meghan Joyce

Darl Moreland

Steve E. Krognes is a professional independent board member in the biotech and life science sector. He currently serves as a director at Denali Therapeutics Inc., Gritstone bio, Inc. and RLS Global AB, and previously served on the board at Corvus Pharmaceuticals, Inc. Before becoming a board member of the company, Mr. Krognes was the chief financial officer of Denali Therapeutics. In this role, he led the company’s IPO efforts and built the corporate finance, information technology and site organizations to enable the company to reach greater scale. Prior to Denali, he served in a variety of roles at large multinational corporations, including chief financial officer at Genentech, Inc. where he led the integration of Genentech and Roche Holding AG in the U.S. and the integration of Genentech and InterMune, Inc. He chaired the Genentech Access to Care Foundation and represented Genentech on the board and executive committee of the California Life Science Association. Prior to Genentech, Mr. Krognes was global head of mergers and acquisitions at Roche. He also worked as an investment banker at Goldman Sachs, as a management consultant at McKinsey & Company and as a venture capitalist in Scandinavia. Mr. Krognes holds a Master of Business Administration from Harvard Business School and a Bachelor of Science in Economics from the Wharton School of the University of Pennsylvania.



Steve E. Krognes

Andy Ament is the SVP of Operations at [Guardant Health](/org/guardant-health). Andy has over 25 years of experience in the biotech industry, including positions at Adaptive Biotechnologies Corp, Genomic Health, Genitope Corporation, and Incyte Genomics. Ament has a degree in Biology from the University of California, Santa Cruz.

Andy Ament studied at the University of California, Davis.

Some of their coworkers include Craig Eagle - Chief Medical Officer, John Saia - SVP, General Counsel & Corporate Secretary, and Kumud Kalia - CIO. Their manager is Helmy Eltoukhy, Co-CEO.

Guardant Health

Org chart

Teams

Leadership Team

CEO and Executive Team

Board of Directors

Discover similar companies